Compounded tirzepatide vs Zepbound bioequivalence evidence (2026)

The honest answer: Compounded tirzepatide is not FDA-tested for bioequivalence to Zepbound. No such study has ever been required, run, or published. The 2022 to late-2024 FDA shortage listing temporarily permitted §503A and §503B compounding; FDA declared the shortage resolved on October 2, 2024, and reaffirmed that declaration on December 19, 2024.^[1]

At a glance

• Zero bioequivalence trials comparing any compounded tirzepatide preparation to FDA-approved Zepbound exist in the public literature.^[2]
• The FDA-approved Zepbound formulation is tirzepatide (a GIP+GLP-1 dual receptor agonist, molecular weight 4813.53 Da, empirical formula C₂₂₅H₃₄₈N₄₈O₆₈) in a sterile aqueous solution. The base peptide is patent-protected by Eli Lilly. Any compounded “tirzepatide” sold outside Lilly’s supply chain is, by definition, not produced under FDA oversight.^[3]
• The §503A and §503B compounding carveouts never required bioequivalence testing. They were designed for patient-specific preparations, not for parallel mass markets.^[1]
• The FDA removed tirzepatide injection from its drug-shortage list on October 2, 2024 and reaffirmed the resolution decision on December 19, 2024 after litigation by the Outsourcing Facilities Association.^[4]
• The FDA’s GLP-1 safety page warns that “patients and health care professionals should be aware that FDA does not review compounded versions of these drugs for safety, effectiveness, or quality.”^[5]
• The FDA’s enforcement wave covering both semaglutide and tirzepatide sellers continued through 2025 and 2026, with warning letters explicitly naming tirzepatide as one of the unapproved active ingredients sold online.^[6][7]

What “bioequivalence” actually means at FDA

The FDA’s definition of bioequivalence is narrow and operational. Two drug products are bioequivalent when “the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action” shows no significant difference at the same molar dose under similar conditions. In practice that means healthy-volunteer pharmacokinetic studies measuring the plasma area under the curve (AUC) and peak concentration (Cmax), with the test product’s 90% confidence interval required to fall within 80–125% of the reference product on both metrics.^[1]

Bioequivalence is the regulatory mechanism by which generic drugs get approved as substitutable for brand-name originators through the Abbreviated New Drug Application (ANDA) pathway. Compounded products are not generic drugs, do not file ANDAs, and by definition have not undergone bioequivalence testing. This is not a loophole; it is the explicit structure of the compounding statute. The situation is more acute for tirzepatide than for semaglutide because tirzepatide remains on-patent and there is no FDA-approved generic version — a true bioequivalent generic would require an ANDA filing that Eli Lilly’s patents currently preclude.^[1]

Anyone marketing a compounded GLP-1 as “bioequivalent to Zepbound” is using the word colloquially (“basically the same”) rather than in the regulatory sense, and the distinction matters because no compounded product on the U.S. market carries the data that would support the regulatory claim.

Zepbound’s FDA-approved formulation (DailyMed verbatim)

The current Zepbound prescribing information on DailyMed describes the active ingredient verbatim as:

“ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C₂₂₅H₃₄₈N₄₈O₆₈.”^[3]

The §3 Dosage Forms and Strengths section lists single-dose prefilled pens and single-dose vials in 2.5, 5, 7.5, 10, 12.5, and 15 mg strengths, each delivering 0.5 mL of solution, and multi-dose KwikPens delivering four doses at the same strengths in 0.6 mL each. Every strength is characterized as a “clear, colorless to slightly yellow, sterile solution” with the active ingredient identified as tirzepatide (no salt qualifier). Excipients include sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection; multi-dose presentations additionally contain benzyl alcohol, glycerin, and phenol as preservatives.^[3]

This matters because tirzepatide is a sequence-specific peptide with two non-natural amino acids (aminoisobutyric acid at positions 2 and 13) and a precisely defined fatty diacid linker. Any compounded preparation must replicate that exact sequence and the exact lipid modification to deliver the same molecule. Substituting any amino acid, altering the linker chemistry, or supplying a salt form produces a different chemical entity that has never been evaluated in SURMOUNT-1 (the pivotal weight-loss trial, Jastreboff et al., 2022, NEJM) or in any other FDA submission.^[8]

How the §503A shortage window enabled the compounded tirzepatide market (2022 to 2024)

Under §503A of the Federal Food, Drug, and Cosmetic Act, a traditional state-licensed compounding pharmacy cannot compound a drug that is “essentially a copy” of a commercially available FDA-approved product. That rule exists to stop compounders from undercutting brand manufacturers on patented medications. The statutory exception is §506E (codified at 21 U.S.C. §356e), which directs the FDA to maintain a public drug-shortage list. When a drug is on that list, the “essentially a copy” prohibition is temporarily lifted.^[1]

Tirzepatide injection was added to the FDA drug-shortage list in December 2022 as Eli Lilly struggled to keep up with Mounjaro and (after the November 2023 approval) Zepbound demand. That listing — which persisted in various dose-strength forms through October 2024 — was the legal hook that made it possible for §503A pharmacies and §503B outsourcing facilities, plus the telehealth platforms that contract with them, to compound and dispense tirzepatide at scale. The §506E carveout was clearly intended to keep hospital infusions and oncology drugs flowing during supply disruptions, not to stand up a parallel direct-to-consumer retail market for weight-loss injections, but the statute does not distinguish.^[4]

FDA’s October and December 2024 declarations

On October 2, 2024, the FDA initially declared the tirzepatide shortage resolved and removed Lilly’s injection from the active shortage list. The Outsourcing Facilities Association (an industry group representing §503B compounders) immediately sued, arguing the FDA had not adequately documented Lilly’s ability to meet demand and that ending the shortage would harm patients depending on compounded supply. In response, the FDA reopened review.^[4]

On December 19, 2024, the FDA reaffirmed its resolution decision and published a detailed rationale. The agency announced a wind-down framework: §503A pharmacies were given until February 18, 2025 to stop compounding tirzepatide that is essentially a copy of Zepbound or Mounjaro, and §503B outsourcing facilities had until March 19, 2025. After those dates, the agency stated, it would treat compounded tirzepatide products as unapproved new drugs and pursue enforcement.^[4]

Verbatim FDA position on compounded tirzepatide post-shortage

The FDA’s dedicated patient-and-provider page on FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss is unambiguous. It states:

“Patients and health care professionals should be aware that FDA does not review compounded versions of these drugs for safety, effectiveness, or quality.”^[5]

The same page specifies that newer GLP-1s including retatrutide and cagrilintide “cannot be used in compounding under federal law” because they are not yet approved at all, separating those investigational molecules from the tirzepatide-specific shortage carveout that briefly applied.^[5]

The page also flags specific recurring failure modes the agency has logged in adverse-event reports tied to compounded GLP-1s: dosing errors (tirzepatide is dosed in fractions of a milligram, and microgram/milligram confusion produces tenfold overdoses); use of salt forms or modified peptide sequences not used in the FDA-approved products; and products from sources without documented quality controls.^[5]

Salt forms, potency variability, and sterility risk

A 2025 analysis of the direct-to-consumer compounded GLP-1 market in Colorado documented that providers routinely market compounded preparations to patients without disclosing the source pharmacy, the API supplier, or whether independent potency and sterility testing has been performed on the lot dispensed.^[2]

Even when the molecule is identical to the Zepbound base peptide, compounded preparations are not required to meet the same potency-band and stability requirements as FDA-approved products. United States Pharmacopeia (USP) chapters governing sterile compounding (notably USP <797>) require sterility and endotoxin testing for finished sterile preparations, but §503A pharmacies are not required to run bioavailability studies, head-to-head clinical comparisons, or long-term stability programs comparable to a brand-name manufacturer. The §503B outsourcing-facility framework layers cGMP requirements on top of USP, narrowing but not eliminating the gap.^[5]

For context on what FDA-approved tirzepatide actually delivers in a controlled trial, the SURMOUNT-1 pivotal study (Jastreboff et al., 2022, NEJM) randomized 2,539 adults with obesity to once-weekly tirzepatide 5, 10, or 15 mg versus placebo and showed mean placebo-adjusted body-weight changes of approximately -15 to -21 percentage points at week 72, depending on dose.^[8] That magnitude reflects the FDA-approved formulation, FDA-approved dosing, and FDA-required quality controls. None of those parameters automatically transfer to a compounded preparation.

Compounded tirzepatide vs Zepbound: what is the same, what is not

The same (in the best case): the target active ingredient — tirzepatide — if the compounding pharmacy in fact sources the identical peptide sequence with the identical fatty-diacid modification. The intended dose strengths (2.5 mg through 15 mg weekly). The intended route (subcutaneous injection).

Not the same: the manufacturing chain of custody (Lilly’s Indianapolis facilities are FDA-inspected cGMP; §503A pharmacy API sourcing is not, and most APIs used in compounded GLP-1s originate from Chinese suppliers registered with the FDA only as bulk-substance manufacturers, not as approved-drug producers). The analytical-release specifications (Lilly tests every lot for identity, potency, purity, and impurities to a proprietary specification reviewed by FDA at approval; a compounder may run only USP <797>-mandated sterility and endotoxin tests on the finished preparation, not on the API). The stability program (Zepbound has documented 24-month refrigerated stability; compounded preparations typically carry a 28-to-90-day beyond-use-date assigned per USP, not validated stability data). The clinical record (every line in the Zepbound prescribing information derives from trials in the FDA-approved formulation; no such record exists for any specific compounded preparation).

FDA enforcement: warning letters covering tirzepatide 2025 to 2026

Since the December 2024 reaffirmation, the FDA Center for Drug Evaluation and Research (CDER) has issued warning letters targeting online sellers of unapproved GLP-1s, with explicit naming of tirzepatide as one of the unapproved active ingredients sold over the internet. Two March 31, 2026 letters cite Prime Sciences^[6] and Mile High Compounds LLC^[7] under the same “Unapproved New Drugs Sold Over the Internet” statutory framing covering both semaglutide and tirzepatide. Two earlier September 9, 2025 letters (against GLP-1 Solution and ASN-LABS) covered the semaglutide side of the same statutory framework. The ongoing live dataset of every FDA warning letter we have identified against GLP-1 compounders is at FDA warning letters to compounded GLP-1 telehealth providers.

The violation pattern across these letters is consistent: marketing as a substitute for FDA-approved Zepbound or Mounjaro without an approved new drug application, misbranding under the Federal Food, Drug, and Cosmetic Act, and in several cases failure to register as a drug manufacturer at all.

If you are on compounded tirzepatide today, what to do

For patients currently using a compounded preparation, the practical checklist is short:

1. Identify the source pharmacy in writing. The telehealth provider should name a specific §503A or §503B facility. “Our network of partner pharmacies” is not an answer.
2. Ask for the API source and certificate of analysis for the finished preparation, documenting identity, potency, sterility, and endotoxin. A pharmacy that cannot produce one on request is a flag.
3. Verify dosing in milligrams, not units or milliliters. The most common compounded-GLP-1 adverse event in FDA reports is microgram/milligram confusion producing tenfold overdoses.^[5]
4. Discuss transition to an FDA-approved product with a clinician. Eli Lilly’s direct-pay channel (LillyDirect) sells single-dose Zepbound vials at structured price tiers and may now be cost-competitive with what compounded providers charge. See Foundayo vs Wegovy vs Zepbound comparison for the current FDA-approved-options landscape.
5. For sister-molecule context, see our Compounded semaglutide vs Wegovy bioequivalence evidence piece — the regulatory framework is identical and the salt-form risks are even more pronounced on the semaglutide side.

Practical takeaway

Compounded tirzepatide is not FDA-bioequivalent to Zepbound, has never been required to be, and the statutory window that briefly legalized its mass-market distribution closed when the FDA reaffirmed the shortage resolution on December 19, 2024. The molecule may or may not be the same active ingredient depending on which API a particular pharmacy sourced. The product may or may not meet the potency it claims depending on which pharmacy compounded it. The agency is now actively enforcing against online sellers through warning letters and is unlikely to reopen the shortage carveout absent a renewed supply disruption.

For molecule-to-molecule context across the compounded landscape, see Compounded tirzepatide vs compounded semaglutide and the matched Compounded semaglutide vs Wegovy bioequivalence evidence review. For investigational and grey-market peptides such as retatrutide, see Retatrutide buy regulatory sourcing evidence.